RxDoctor Payments Data

Judd Bauer, MD

Nephrology · Omaha, NENPI 1982833554

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,100 of the $3,476 with a category attached, or 60.4%. Novartis accounts for 61.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $2,270 and has fallen 62.5% since, to $852 in 2025.

$3,476in general payments, 2019–2025

Across 89 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Bayer$233
  • ANI Pharmaceuticals, Inc.$180
  • Travere Therapeutics, Inc.$173
  • Amgen$118
  • Bard Peripheral Vascular, Inc.$115
  • plus $525 from 15 others

What the payments were for

  • Consulting fees$2,10060%
  • Food & beverage$1,33638%
  • Education$401%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,476 in reported general payments places this provider in the 75th percentile of 60 nephrology providers in Nebraska.

See all nephrology providers in Nebraska

Medicare billing

Part B allowed, 2024
$206,879
Medicare patients
556
Services billed
3,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol24$25,899
KerendiaFinerenone15$18,998
Doxazosin Mesylate38$1,541
Torsemide52$1,511
Calcitriol56$1,240
Nifedipine ErNifedipine20$734
Amlodipine Besylate88$519
Metoprolol Succinate21$501
Carvedilol58$484
Tamsulosin Hcl54$466
Potassium Chloride32$439
Furosemide95$403
Lisinopril42$398
Prednisone35$348
Telmisartan20$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$47$25,89924 claims
BayerKerendia$233$18,99815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 60 nephrology providers in Nebraska.

Other nephrology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →